Effects of single dose GnRH agonist as luteal support on pregnancy outcome in frozen-thawed embryo transfer cycles: an RCT.

Davar R, Farid Mojtahedi M, Miraj S

Iranian journal of reproductive medicine1 Aug 2015Cited by 15 (Europe PMC)

PMID26568750PMCIDPMC4637112PepBankPUB-26568750

Summary

BackgroundThere is no doubt that luteal phase support is essential to enhance the reproductive outcome in IVF cycles. In addition to progesterone and human chorionic gonadotropin, several studies have described GnRH agonists as luteal phase support to improve implantation rate, pregnancy rate and live birth rate, whereas other studies showed dissimilar conclusions. All of these studies have been done in fresh IVF cycles.ObjectiveTo determine whether an additional GnRH agonist administered at the time of implantation for luteal phase support in frozen-thawed embryo transfer (FET) improves the embryo developmental potential.Materials and methodsThis is a prospective controlled trial study in 200 FET cycles, patients were randomized on the day of embryo transfer into group 1 (n=100) to whom a single dose of GnRH agonist (0.1 mg triptorelin) was administered three days after transfer and group 2 (n=100), who did not receive agonist. Both groups received daily vaginal progesterone suppositories plus estradiol valerate 6 mg daily. Primary outcome measure was clinical pregnancy rate. Secondary outcome measures were implantation rate, chemical, ongoing pregnancy rate and abortion rate.ResultsA total of 200 FET cycles were analyzed. Demographic data and embryo quality were comparable between two groups. No statistically significant difference in clinical and ongoing pregnancy rates was observed between the two groups (26% versus 21%, p=0.40 and 21% versus 17%, p=0.37, respectively).ConclusionAdministration of a subcutaneous GnRH agonist at the time of implantation does not increase clinical or ongoing pregnancy.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In frozen-thawed embryo transfer cycles, added triptorelin did not significantly change clinical pregnancy versus progesterone and estradiol alone.
In plain wordsClinical pregnancy rates were similar with added triptorelin and with progesterone and estradiol alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeClinical pregnancy
Study
n = 200
Comparator
Progesterone and estradiol without triptorelin
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Single 0.1 mg dose · subcutaneousAs given in this study (human).
Measurements
Clinical pregnancy
26%
triptorelin
Clinical pregnancy
21%
control
Source sentences
Summary
No statistically significant difference in clinical and ongoing pregnancy rates was observed between the two groups (26% versus 21%, p=0.40 and 21% versus 17%, p=0.37, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a prospective controlled trial study in 200 FET cycles, patients were randomized on the day of embryo transfer into group 1 (n=100) to whom a single dose of GnRH agonist (0.1 mg triptorelin) was administered three days after transfer and group 2 (n=100), who did not receive agonist.
Summary · context
Both groups received daily vaginal progesterone suppositories plus estradiol valerate 6 mg daily.
Show in the study text Report a problemFND-2656875001
02HumanRandomized controlled trialEfficacy outcome
In frozen-thawed embryo transfer cycles, added triptorelin did not significantly change ongoing pregnancy versus progesterone and estradiol alone.
In plain wordsOngoing pregnancy rates were similar with added triptorelin and with progesterone and estradiol alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOngoing pregnancy
Study
n = 200
Comparator
Progesterone and estradiol without triptorelin
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Single 0.1 mg dose · subcutaneousAs given in this study (human).
Measurements
Ongoing pregnancy
21%
triptorelin
Ongoing pregnancy
17%
control
Source sentences
Summary
No statistically significant difference in clinical and ongoing pregnancy rates was observed between the two groups (26% versus 21%, p=0.40 and 21% versus 17%, p=0.37, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a prospective controlled trial study in 200 FET cycles, patients were randomized on the day of embryo transfer into group 1 (n=100) to whom a single dose of GnRH agonist (0.1 mg triptorelin) was administered three days after transfer and group 2 (n=100), who did not receive agonist.
Summary · context
Both groups received daily vaginal progesterone suppositories plus estradiol valerate 6 mg daily.
Show in the study text Report a problemFND-2656875002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT04174378

Luteal Phase Support In IVF Women Using GnRH Agonist

National University of Malaysian = 22229 Nov 2018 to 18 Nov 2019

IVF · Luteal Phase Defect

Trial page ClinicalTrials.govUpdated 25 Nov 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.